RESPROTECT GMBH has a total of 32 patent applications. Its first patent ever was published in 1996. It filed its patents most often in Germany, EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are BONNIE DAVIS, BIOLAB SANUS FARMACEUTICA LTDA and BLATT LAWRENCE M.
# | Country | Total Patents | |
---|---|---|---|
#1 | Germany | 5 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | United States | 4 | |
#4 | Australia | 3 | |
#5 | Canada | 3 | |
#6 | China | 3 | |
#7 | Republic of Korea | 2 | |
#8 | Mexico | 2 | |
#9 | Brazil | 1 | |
#10 | Hong Kong | 1 | |
#11 | Hungary | 1 | |
#12 | Norway | 1 | |
#13 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology | |
#4 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Climate change adaptation technologies | |
#5 | Sugars | |
#6 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Fahrig Rudolf | 23 |
#2 | Heinrich Joerg-Christian | 15 |
#3 | Krupitza Georg | 8 |
#4 | Dieks Henrik | 7 |
#5 | Lohmann Dieter | 7 |
#6 | Teubner Janek | 7 |
#7 | Rolfs Andreas | 7 |
#8 | Georg Krupitza | 4 |
#9 | Fahrig Rudolf Hinrich Hermann | 4 |
#10 | Rudolf Fahrig | 4 |
Publication | Filing date | Title |
---|---|---|
DE102008035299A1 | Conjugate, particularly bromovinyl-deoxyuridine for manufacture medicament for inhibiting or suppressing metastasis including distant metastases in cytostatic treatment, includes heat shock protein and nucleoside | |
DE102008030091A1 | Uracil derivatives and their use | |
CA2601558A1 | Method of treating cancer by administration of 5-substituted nucleosides | |
US2009068286A1 | Method of treating cancer by administration of 5-substituted nucleosides | |
DE102006037786A1 | Nucleosides, pharmaceuticals containing them and their use | |
DE10313035A1 | Method to increase the apoptotic effect of cytostatics without increasing toxic side effects | |
DE10108851A1 | Use of 5'-substituted nucleosides and / or their prodrugs for the resistance-free therapy of infectious diseases | |
EP0806956A1 | Use of 5'substituted nucleosides to provide resistance in cytostatic treatment |